Recon: Shkreli Sentenced to 7 Years

• Despite FDA concerns, Pfizer's Xeljanz wins unanimous AdComm backing in ulcerative colitis (Fierce) (Reuters) (PharmaTimes) (MedPage Today)
• Shkreli sentenced to 7 years on felony fraud (WSJ)
• Judge orders 1,200 Xarelto liability cases to be prepped for trials (Fierce)
• Sanofi Clears a Hurdle in Bribery Probe (WSJ) (Fierce)
• Amazon’s pharmacy hires hint of ambitions to upend a $360 billion market (STAT-$) (Becker’s Hospital Review)
• Flu vaccine grown without eggs provided measurably better protection this season, FDA says (STAT) (Focus) (CNN)
• Doctor in a Opioid Kickback Scheme Due to Be Sentenced (AP News) (Reuters)
• Trump officials tell Idaho it can’t dump Obamacare (Politico) (Reuters) (CNN) (Bloomberg)
• FDA Approves 2 Cinacalcet Hydrochloride Generics for HPT Market Competition (MD Magazine) (Focus)

• Launch a joint research call with Spain SEIDI (Japan Agency for Medical Research and Development)
• EU expands scope of GSK/Innoviva’s asthma inhaler (PharmaTimes) (Pharmabiz.com)
• WuXi NextCODE and Google Cloud partner to enhance global genomic access (Fierce)
• Diabetes Drug Developer Hua Picks Hong Kong for IPO (Bloomberg) (Reuters) (Endpoints News)
• NHS staff to be offered pay rise for giving up day's holiday, leaked document reveals (The Telegraph)

• Biotech boss Jackie Hunter takes aim at male tech culture (Financial Times)
• Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics (Press)
• Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood—Brain Barrier: Proceedings of a Workshop (National Academy of Sciences)
• Genentech Fights For $5.8M In ‘Exceptional' IP Attys Fees (Law360-$)
• ICER Weekly View 03-09-18 (ICER)
• AI-driven drug discovery startup Atomwise raises $45M series A (Fierce)
• Johnson & Johnson's $15B in 2017 discounts lead to negative price change, but are consumers benefiting? (Fierce)
• MSKCC’s Maura Dickler to become Eli Lilly’s new late-stage cancer R&D lead (Fierce) (Press)
• Nimbus founding CSO Rosana Kapeller leaves to explore exec role; AI startup BioXcel pockets $60M from IPO (Endpoints News) (Fierce) (Press)
• Senators heap abuse on Allergan’s attempt at an end run around patent reviews, offer bill to stop ‘sham’ (Endpoints News)

• Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes (Pink Sheet-$)
• Synthetic polymers could be the silver bullet for multidrug-resistant superbugs (Fierce)
• AM-Pharma still on track with sepsis drug despite mixed phase 2 readout (Fierce) (Press)
• MyoKardia steps closer to the launch of a groundbreaking heart trial after finding its low-dose starting point (Endpoints News) (Fierce)
• Voyager’s gene therapy for Parkinson’s shows promise in early data from small Phase Ib trial (Endpoints News) (Press)
• Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies (Forbes)
• Trial And Error, Or The Problem Of Clinical Trial Data Exclusivity (Above The Law)
• Why Not Do A Randomized Trial Of Precision Oncology? (Forbes)
• Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting (Press)
• FDA sets path for stem cell therapies (CNN)
• TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR (Press)
• US cancer network recommending expensive drugs based on weak evidence, study finds (The Guardian)

• Xeris hauls $55M in new funding to bring glucagon pen to market (Endpoints News) (Press)
• Two Women Are Building A Pregnancy Test-Like Device To Spot Cervical Cancer (Forbes)
• Clinical systems tech companies unwrap new applications at HIMSS18 (Healthcare IT News)
• J&J CIO touches on FDA pre-cert pilot program, artificial intelligence and innovation (MedCity News)
• Medtronic’s MiniMed 670G insulin delivery system gave me peace of mind (MedCity News)
• Somatix Takes The Activity Tracker From An Athletic Option To A Clinical Imperative (Forbes)
• Polyganics liver and pancreas sealant wins FDA breakthrough designation (MassDevice) (Press)
• WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents (Press)
• LivaNova finalizes details in $190m CRM sale to MicroPort (MassDevice)
• Valencia Tech wins FDA nod for eCoin neurostim overactive bladder trial (MassDevice) (Press)
• Alphatec raises $50m, acquires SafeOp Surgical (MassDevice)
• Inovalon to buy ABILITY for $1.2 billion (Healthcare IT News)
• Enhatch Develops Fit2Kit Patient-Driven Technology Platform For Medical Device Manufacturers And Orthopedic Surgeons (Press)
• GE Additive launches Orthopaedic Validation Consultancy for metal AM medical devices (Metal Additive Manufacturing magazine)
• PrescribeWellness Partners With Venebio to Help Local Pharmacies Address the Opioid Epidemic (Press)
•  Magellan Expands Digital Innovation Platform and Strategy (Press)

• Health Officials Assail ‘Pricing Schemes’ That Gouge Patients (NYT)
• Merck C.E.O. Ken Frazier on Death Row Cases and the Corporate Soul (NYT)
• Senator Murray Emphasizes Need for Federal Government to Support State Innovation to Address Opioid Crisis (HELP Committee)
• The Martin Shkreli saga ends today, but the issue he raised on drug pricing seems immortal (Endpoints News)
• Pharmalittle: J&J says average prices paid for its drugs declined; feds will use false claims to crack down on opioid abuse (STAT-$)
• Shkreli Lawyer Says He Alternately Wants to Punch and Hug Client (Bloomberg)
• Cigna to Draw Antitrust Scrutiny Amid Health-Care Deal Wave (Bloomberg)
• With Express Scripts Debt, Cigna Needs Anthem Break-Up Money (Forbes)
• Human API and CMS collaborate to help Medicare patients share claims data in new chapter for Blue Button (MedCity News)
• NQF Issues Critical Guidance to Support Safer Opioid Prescribing (NQF)

• FDA Advisory Committee Calendar
• Reauthorization of Animal Drug User Fees 2018: ADUFA and AGDUFA

• MHRA Freedom of Information Act (FOIA) request Disclosure Log index (MHRA)
• Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 March 2018 (EMA)

• WuXi Biologics is producing a newly approved HIV med in the first Chinese biologics plant approved by the FDA (Fierce) (Press)
• Teleflex settles spat with Chinese distributor (MassDevice)

• Microsoft, Apollo Hospitals to employ AI for early detection of cardiac diseases (Healthcare IT News)
• Govt committed to making healthcare services affordable: MoS Health (Times of India)
• Why Potentially Dodgy Diabetes Drugs Dominate in India (NPR)
• Pulsus opens healthcare informatics, pharmacovigilance facility in Chennai (Times of India)

• Section 23 instruments (TGA)
• Recall - potential risk of harm for children who access the button battery (TGA)
• Shares in Australian pharma Immuron are going nuts (Business Insider)
• Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia (Press)
• 'Unprecedented': Health costs the Australian economy $40 billion per quarter (The Sydney Morning Herald)
• Nation losing the battle to keep kids safe (The Australian)

• TearLab loses Canadian patent spat with i-Med Pharma (MassDevice)
• Health Canada Warns Women Not To Take Chipped Birth Control Pills (HuffPost Canada)
• More chipped birth control pills found in Apotex's Alysena products (CBC)

• Beware this insurer’s sneak attack on emergency care coverage (STAT)
• For diabetics, a high-fiber diet feeds gut microbes, lowering blood sugar (STAT)
• America Is Giving Away the $30 Billion Medical Marijuana Industry (Bloomberg)
• Survey: Health app adoption has tripled since 2014 (mobihealthnews)
• How NASA's telemedicine doctors keep International Space Station astronauts healthy (Healthcare IT News)
• Fewer heart attack patients die when top cardiologists are away at conferences, study finds (The Telegraph)